Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Last updated: July 18, 2025
Sponsor: Glaukos Corporation
Overall Status: Active - Recruiting

Phase

2/3

Condition

Glaucoma

Treatment

Gen 2 Travoprost Intracameral Implant

Timolol eye drops 0.5%

Sham Procedure

Clinical Study ID

NCT07075718
GLK-102-01
  • Ages > 18
  • All Genders

Study Summary

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of open-angle glaucoma or ocular hypertension in the study eye

Exclusion

Exclusion Criteria:

  • Prior incisional glaucoma surgery in the study eye

  • Prior argon laser trabeculoplasty (ALT) in the study eye

  • Prior minimally invasive glaucoma (MIGS) surgery in the study eye

Study Design

Total Participants: 610
Treatment Group(s): 4
Primary Treatment: Gen 2 Travoprost Intracameral Implant
Phase: 2/3
Study Start date:
June 12, 2025
Estimated Completion Date:
March 31, 2032

Study Description

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Compared to Timolol Ophthalmic Solution 0.5% Administered Twice Daily in Subjects with Open-Angle Glaucoma or Ocular Hypertension

Connect with a study center

  • Glaukos Investigative Site

    Grand Junction, Colorado 81501
    United States

    Active - Recruiting

  • Glaukos Investigative Site

    Oklahoma City, Oklahoma 73112
    United States

    Active - Recruiting

  • Glaukos Clinical Site

    El Paso, Texas 79922
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.